Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

Neurology

Volumn 89, Issue 19, 2017, Pages 1959-1969

  Mollenhauer, Brit ^a,b   Caspell Garcia, Chelsea J ^c   Coffey, Christopher S ^c   Taylor, Peggy ^d   Shaw, Leslie M ^e   Trojanowski, John Q ^e   Singleton, Andy ^f   Frasier, Mark ^g   Marek, Kenneth ^h   Galasko, Douglas ⁱ  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b PARACELSUS ELENA KLINIK   (Germany)

^c UNIVERSITY OF IOWA   (United States)

^d BIOLEGEND   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^h INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; IOFLUPANE I 123; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE EXACERBATION; FOLLOW UP; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NEUROIMAGING; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SUBSTITUTION THERAPY; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; CASE CONTROL STUDY; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TIME FACTOR;

AGED; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; DOPAMINE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 85033600060     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004609     Document Type: Article

References (36)

1. Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2012;2:a008888.
2. Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 2015;16: 109-120.
3. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
4. Tapiola T, Overmyer M, Lehtovirta M, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997;8:3961-3963.
5. Tokuda T, Salem SA, Allsop D, et al. Decreased alphasynuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-166.
6. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-240.
7. Hong Z, Shi M, Chung KA, et al. DJ-1 and alphasynuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-726.
8. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277-1287.
9. Kang JH, Mollenhauer B, Coffey CS, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol 2016;131:935-949.
10. Majbour NK, Vaikath NN, Eusebi P, et al. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. Mov Disord 2016;31:1535-1542.
11. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol 2012;69:1445-1452.
12. Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014;184:966-975.
13. Zhang J, Mattison HA, Liu C, et al. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013;126:671-682.
14. Mollenhauer B, Zimmermann J, Sixel-Doring F, et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 2016;87:168-177.
15. Gomperts SN, Locascio JJ, Makaretz SJ, et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol 2016;73:1334-1341.
16. Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 2017;16:55-65.
17. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635.
18. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
19. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
20. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire: a new diagnostic instrument. Mov Disord 2007;22:2386-2393.
21. Nalls MA, Keller MF, Hernandez DG, et al. Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI). Mov Disord 2016;31:79-85.
22. Wang Y, Shi M, Chung KA, et al. Phosphorylated alphasynuclein in Parkinson's disease. Sci Transl Med 2012;4: 121ra120.
23. Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther 2014;6:25.
24. Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 2017;74:163-172.
25. Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014;6:226ra230.
26. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
27. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015;14: 57-64.
28. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015;72:863-873.
29. Vendette M, Gagnon JF, Decary A, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007;69:1843-1849.
30. Toledo JB, Vanderstichele H, Figurski M, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011;122:401-413.
31. Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol 2017; 16:66-75.
32. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first crosssectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-325.
33. Mignini F, Bronzetti E, Felici L, et al. Dopamine receptor immunohistochemistry in the rat choroid plexus. J Auton Pharmacol 2000;20:325-332.
34. Chau KY, Cooper JM, Schapira AH. Pramipexole reduces phosphorylation of alpha-synuclein at serine-129. J Mol Neurosci 2013;51:573-580.
35. Yu X, Yao JY, He J, Tian JW. Protection of MPTPinduced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres. Life Sci 2015;124: 136-143.
36. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75: 1766-1772.